Brooke McCormick

Data from the phase 3 BREAKWATER trial supported full FDA approval of the encorafenib combination for metastatic CRC with a BRAF V600E mutation, demonstrating significant survival gains.

The increase in CRC-related mortality in younger adults is driven by screening delays and advanced-stage diagnoses, according to Jordan Karlitz, MD.

FDA draft guidance outlines a new pathway to speed up approval of individualized genome and RNA therapies for rare diseases when RCTs are not feasible.

FDA approves 4-dose KwikPen for tirzepatide (Zepbound; Eli Lilly), offering a full month of weight management treatment in 1 device.

Many eligible patients miss lung cancer screening due to low awareness and systemic barriers, putting underserved groups at higher risk for late-stage disease.

Kathrin Dvir, MD, MSc, concludes by highlighting the importance of outreach, education, and trusted messaging to improve breast cancer screening adherence.

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Sora Ely, MD, emphasized that national lung cancer screening rates remain below 10%, underscoring the urgent need for greater awareness and uptake.

Kathrin Dvir, MD, MSc, discusses how biomarker-driven care, targeted therapies, and evolving sequencing are shaping modern breast cancer treatment.

To conclude his conversation with AJMC, Jordan Karlitz, MD, outlines clinical, behavioral, and policy strategies to reverse rising CRC deaths in adults aged under 50.

Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.

Today's approval enables once-monthly SC amivantamab dosing for patients with EGFR-mutant NSCLC, reducing clinic visits without compromising efficacy or safety.

Jordan Karlitz, MD, highlights racial, ethnic, and socioeconomic disparities in rising CRC mortality rates among younger adults, driven by gaps in screening and awareness.

Individuals can use these 5 ways to minimize their cancer risk during National Cancer Prevention Month and beyond.

Jordan Karlitz, MD, explains the rise in CRC-related deaths in younger adults, stressing the need for earlier screening and symptom awareness.

Vishal A. Patel, MD, shares skin cancer prevention tips, highlighting sun-smart habits, risk-based screening, and at-home early detection.

As more oral cancer therapies become available, medically integrated dispensing models are increasingly vital, says Kenneth Komorny, PharmD, BCPS.

Susan Vadaparampil, PhD, MPH, explains that aligning clinical trials with community needs can improve enrollment diversity.

Ameet Patel, MD, discusses scaling CAR T-cell therapy and bispecific therapies to improve access and potentially cure multiple myeloma.

Vishal A. Patel, MD, explains that delayed skin cancer diagnoses contribute to more advanced disease and poorer outcomes in patients with darker skin.

Medically integrated dispensing (MID) models help build patient trust in pharmacists, which can help improve adherence, explains Kenneth Komorny, PharmD, BCPS.

Patient navigators, community health workers, and/or peer advocates serve as trusted community resources for patients, Susan Vadaparampil, PhD, MPH, says.

The postpandemic reinstatement of Medicare’s 3-day rule lengthened hospital stays without affecting SNF use, spending, or short-term outcomes, raising questions about its value.

Medically integrated dispensing is well-positioned to support value-based oncology care models and closer patient follow-up and monitoring, says Katherine Tobon, PharmD, BCOP.

To protect patients, the FDA will restrict ingredients in unapproved compounded GLP‑1 drugs and crack down on misleading marketing.

MID in oncology also enhances treatment adherence and improves patient outcomes, according to Kenneth Komorny, PharmD, BCPS.

Medically integrated dispensing (MID) improves monitoring and supports value-based care, but startup costs and payer barriers remain, notes Katherine Tobon, PharmD, BCOP.

Susan Vadaparampil, PhD, MPH, highlights disparities in cancer outcomes and trial enrollment but underscores that linking community screening programs with cancer centers may help.

Targeted therapies, bispecifics, and CAR T-cell therapies are giving patients with multiple myeloma hope for long-term remission or a potential cure.

A deep-learning serial CT response score outperformed conventional imaging measures in predicting OS for patients with advanced NSCLC treated with ICIs.